Enliven Therapeutics (NASDAQ:ELVN) Now Covered by HC Wainwright

Analysts at HC Wainwright began coverage on shares of Enliven Therapeutics (NASDAQ:ELVN) in a research note issued on Monday, Briefing.com reports. The firm set a “buy” rating and a $37.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 72.57% from the stock’s current price.

Several other research analysts have also commented on ELVN. Robert W. Baird started coverage on Enliven Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price target for the company. Baird R W raised shares of Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th.

Enliven Therapeutics Price Performance

ELVN opened at $21.44 on Monday. Enliven Therapeutics has a 12-month low of $9.80 and a 12-month high of $27.67. The stock has a market capitalization of $1.01 billion, a PE ratio of -11.11 and a beta of 1.10. The firm’s fifty day moving average price is $23.08 and its 200 day moving average price is $20.80.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. On average, equities research analysts forecast that Enliven Therapeutics will post -2.02 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Joseph P. Lyssikatos sold 3,099 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $27.56, for a total transaction of $85,408.44. Following the sale, the insider now directly owns 1,089,936 shares in the company, valued at approximately $30,038,636.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Joseph P. Lyssikatos sold 3,099 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $27.56, for a total transaction of $85,408.44. Following the completion of the transaction, the insider now owns 1,089,936 shares in the company, valued at $30,038,636.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $21.66, for a total transaction of $259,920.00. Following the completion of the sale, the chief executive officer now owns 1,075,525 shares in the company, valued at $23,295,871.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 135,805 shares of company stock valued at $3,328,112. 29.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELVN. China Universal Asset Management Co. Ltd. grew its stake in shares of Enliven Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after purchasing an additional 3,189 shares in the last quarter. EntryPoint Capital LLC bought a new position in Enliven Therapeutics in the 1st quarter valued at about $167,000. Baker BROS. Advisors LP acquired a new position in Enliven Therapeutics during the 1st quarter valued at about $2,020,000. Blackstone Inc. acquired a new position in Enliven Therapeutics during the 1st quarter valued at about $443,000. Finally, Janus Henderson Group PLC raised its position in shares of Enliven Therapeutics by 74.8% during the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after buying an additional 305,397 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.